Published in Emerg Infect Dis on May 01, 2007
Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis (2009) 5.96
Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium. J Clin Microbiol (2007) 1.79
Buruli ulcer in South Western Nigeria: a retrospective cohort study of patients treated in Benin. PLoS Negl Trop Dis (2015) 0.92
Buruli ulcer in Liberia, 2012. Emerg Infect Dis (2014) 0.78
Buruli ulcer in Nigeria: results of a pilot case study in three rural districts. Infect Dis Poverty (2016) 0.75
Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis (2004) 3.08
Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg (2004) 2.29
Mycobacterium ulcerans (Buruli) skin ulceration in Nigeria. Am J Trop Med Hyg (1976) 1.58
Mycobacterial skin ulcers in Nigeria. Trans R Soc Trop Med Hyg (1967) 1.21
Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol (2006) 11.86
Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet (2006) 4.73
Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 4.10
Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med (2005) 4.00
Mass treatment with single-dose azithromycin for yaws. N Engl J Med (2015) 3.84
Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis (2002) 3.41
Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis (2004) 3.08
Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. avium for bird-type isolates and 'M. avium subsp. hominissuis' for the human/porcine type of M. avium. Int J Syst Evol Microbiol (2002) 3.02
Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis (2006) 2.73
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg (2004) 2.29
Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res (2006) 2.15
Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol (2006) 2.10
Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun (2003) 2.08
Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin. Trop Med Int Health (2003) 2.07
Genotyping Mycobacterium ulcerans and Mycobacterium marinum by using mycobacterial interspersed repetitive units. J Bacteriol (2005) 2.06
Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. J Clin Microbiol (2004) 2.06
Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother (2003) 1.93
Risk factors for buruli ulcer: a case control study in Cameroon. PLoS Negl Trop Dis (2007) 1.90
Buruli ulcer (Mycobacterium ulcerans infection). Trans R Soc Trop Med Hyg (2008) 1.88
Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS One (2009) 1.87
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother (2009) 1.82
Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother (2006) 1.80
Mycobacteria in drinking water distribution systems: ecology and significance for human health. FEMS Microbiol Rev (2005) 1.79
Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium. J Clin Microbiol (2007) 1.79
Multilocus variable-number tandem repeat typing of Mycobacterium ulcerans. J Clin Microbiol (2005) 1.77
Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother (2010) 1.72
The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother (2008) 1.71
High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother (2009) 1.69
Buruli ulcer recurrence, Benin. Emerg Infect Dis (2005) 1.69
One-tube cell lysis and DNA extraction procedure for PCR-based detection of Mycobacterium ulcerans in aquatic insects, molluscs and fish. J Med Microbiol (2004) 1.59
Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun (2005) 1.59
On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics (2012) 1.58
Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol (2004) 1.57
Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother (2005) 1.53
Buruli ulcer distribution in Benin. Emerg Infect Dis (2005) 1.52
Rapid alternative methods for detection of rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother (2004) 1.51
Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg (2009) 1.49
Yaws eradication: past efforts and future perspectives. Bull World Health Organ (2008) 1.48
Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis (2010) 1.48
Yaws. Lancet (2013) 1.47
Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol (2006) 1.45
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun (2006) 1.45
Genetic diversity in Mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol (2006) 1.44
Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. Am J Trop Med Hyg (2006) 1.42
Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin (2011) 1.37
Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol (2009) 1.34
Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay. J Clin Microbiol (2006) 1.34
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother (2013) 1.27
Detection of Mycobacterium ulcerans in the environment predicts prevalence of Buruli ulcer in Benin. PLoS Negl Trop Dis (2012) 1.27
Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis (2009) 1.27
Buruli ulcer surveillance, Benin, 2003-2005. Emerg Infect Dis (2007) 1.20
Newly developed primers for the detection of Mycobacterium avium subspecies paratuberculosis. Vet Microbiol (2004) 1.19
PCR amplification with primers based on IS2404 and GC-rich repeated sequence reveals polymorphism in Mycobacterium ulcerans. J Clin Microbiol (2005) 1.19
Family relationship, water contact and occurrence of Buruli ulcer in Benin. PLoS Negl Trop Dis (2010) 1.16
A comparison of DNA extraction procedures for the detection of Mycobacterium ulcerans, the causative agent of Buruli ulcer, in clinical and environmental specimens. J Microbiol Methods (2008) 1.16
Buruli ulcer: a systemic disease. Clin Infect Dis (2003) 1.16
Ongoing genome reduction in Mycobacterium ulcerans. Emerg Infect Dis (2007) 1.16
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
Heterogeneity among Mycobacterium ulcerans isolates from Africa. Emerg Infect Dis (2006) 1.13
Comparative nucleotide sequence analysis of polymorphic variable-number tandem-repeat Loci in Mycobacterium ulcerans. J Clin Microbiol (2005) 1.13
Terrestrial small mammals as reservoirs of Mycobacterium ulcerans in benin. Appl Environ Microbiol (2010) 1.13
Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control? PLoS Med (2007) 1.11
A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother (2006) 1.11
Buruli ulcer: a review of in vitro tests to screen natural products for activity against Mycobacterium ulcerans. Planta Med (2011) 1.10
Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies. Med J Aust (2007) 1.09
Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS (2008) 1.08
African 2, a clonal complex of Mycobacterium bovis epidemiologically important in East Africa. J Bacteriol (2010) 1.08
The return of yaws. Bull World Health Organ (2008) 1.07
Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli ulcer) in Benin. Am J Trop Med Hyg (2007) 1.07
VNTR analysis differentiates Mycobacterium ulcerans and IS2404 positive mycobacteria. Syst Appl Microbiol (2007) 1.07
Mycobacterium ulcerans disease, Peru. Emerg Infect Dis (2008) 1.07
BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. Am J Trop Med Hyg (2006) 1.06
Application of real-time PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobacterium ulcerans in the environment. FEMS Microbiol Lett (2010) 1.06
New foci of Buruli ulcer, Angola and Democratic Republic of Congo. Emerg Infect Dis (2008) 1.06
Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009) 1.05
Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the nitrate reductase assay using liquid medium and direct application to sputum samples. J Clin Microbiol (2008) 1.05
Therapeutic itineraries of patients with ulcerated forms of Mycobacterium ulcerans (Buruli ulcer) disease in a rural health zone in the Democratic Republic of Congo. Trop Med Int Health (2009) 1.04
Amoebae as potential environmental hosts for Mycobacterium ulcerans and other mycobacteria, but doubtful actors in Buruli ulcer epidemiology. PLoS Negl Trop Dis (2012) 1.03
First detection of mycobacteria in African rodents and insectivores, using stratified pool screening. Appl Environ Microbiol (2007) 1.02
Occurrence of free-living amoebae in communities of low and high endemicity for Buruli ulcer in southern Benin. Appl Environ Microbiol (2008) 1.02
Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. AIDS (2002) 1.02
Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays. J Clin Microbiol (2005) 1.02
Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection). Curr Opin Infect Dis (2010) 1.01
First case of Mycobacterium ulcerans disease (Buruli ulcer) following a human bite. Clin Infect Dis (2003) 1.01
Multicenter evaluation of mycobacteria identification by PCR restriction enzyme analysis in laboratories from Latin America and the Caribbean. J Microbiol Methods (2004) 1.01
Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun (2010) 1.00
Diversity of Mycobacterium tuberculosis genotypes circulating in Ndola, Zambia. BMC Infect Dis (2010) 1.00
European 1: a globally important clonal complex of Mycobacterium bovis. Infect Genet Evol (2011) 0.98
Sero-epidemiology as a tool to screen populations for exposure to Mycobacterium ulcerans. PLoS Negl Trop Dis (2012) 0.98
Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms. Am J Trop Med Hyg (2010) 0.98
Low Occurrence of Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a Long-Running DOTS Program in Zambia. Tuberc Res Treat (2010) 0.98
Insertion sequence element single nucleotide polymorphism typing provides insights into the population structure and evolution of Mycobacterium ulcerans across Africa. Appl Environ Microbiol (2013) 0.98